Analysis of Attitudes and Practices towards the Influenza Vaccine in High-Risk Adults in Poland-Reference-Cited by-同舟云学术

Analysis of Attitudes and Practices towards the Influenza Vaccine in High-Risk Adults in Poland

Published:2024-03-21 Issue:3 Volume:12 Page:341
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Kopciuch Dorota¹,Hoffmann Karolina²^ORCID,Kus Krzysztof¹,Koligat-Seitz Agnieszka³,Ratajczak Piotr¹^ORCID,Nowakowska Elżbieta⁴^ORCID,Paczkowska Anna¹^ORCID

Affiliation:

1. Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3 Street, 60-806 Poznan, Poland

2. Department of Internal Diseases, Metabolic Disorders and Arterial Hypertension, Poznan University of Medical Sciences, Szamarzewskiego 84 Street, 60-572 Poznan, Poland

3. Department of Otolaryngology, Greater Poland Pediatric Center, Wrzoska 1 Street, 60-663 Poznan, Poland

4. Department of Pharmacology and Toxicology, Institute of Health Sciences, Collegium Medicum, University of Zielona Gora, Licealna 9 Street, 65-417 Zielona Góra, Poland

Abstract

This study aimed to understand Poles’ attitudes and beliefs towards influenza vaccinations in the flu season of 2022–2023, especially among individuals at risk of flu complications. The cross-sectional survey-based study was carried out on a sample of 810 respondents. The questionnaire was disseminated electronically using social media and e-mail. The majority of respondents (71%) could identify “high-risk groups” recommended for influenza vaccination, and 52.01% of respondents reported receiving influenza vaccination at some point in the past, with 32.12% receiving it in the 2022–2023 flu season and 41.09% in the 2021–2022 season. The majority of respondents declaring acceptance of the vaccine for the 2022–2023 season were in the high-risk group. Only 17.28% of respondents declared receiving both influenza and SARS-CoV-2 vaccines in the 2022–2023 season, with the vast majority being respondents from the “high-risk group” (p < 0.0001). Only 26.12% of respondents declared their intention to continue influenza vaccination in the future. Of those expressing the intention to get vaccinated against the influenza virus in future seasons, 46.79% were from the “high-risk group” (p = 0.0087). Results suggest the need for further interaction and education with healthcare providers and targeted informational efforts for at-risk groups regarding the benefits of flu vaccination.

Funder

Poznan University of Medical Sciences

Publisher

MDPI AG

Link

https://www.mdpi.com/2076-393X/12/3/341/pdf

Reference37 articles.

1. World Health Organization (2012). Vaccines against Influenza WHO Position Paper—November 2012. Wkly. Epidemiol. Rec., 87, 461–476.

2. (2024, February 05). Mortality, Morbidity, and Hospitalisations Due to Influenza Lower Respiratory Tract Infections, 2017: An Analysis for the Global Burden of Disease Study 2017—The Lancet Respiratory Medicine. Available online: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(18)30496-X/fulltext.

3. (2024, February 05). Seasonal Influenza Vaccination Strategies. Available online: https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/vaccination-strategies.

4. (2024, February 05). Seasonal Influenza Vaccination and Antiviral Use in EU/EEA Member States. Available online: https://www.ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-antiviral-use-eu-eea-member-states.

5. Van Kerkhove, M.D., Vandemaele, K.A.H., Shinde, V., Jaramillo-Gutierrez, G., Koukounari, A., Donnelly, C.A., Carlino, L.O., Owen, R., Paterson, B., and Pelletier, L. (2011). Risk Factors for Severe Outcomes Following 2009 Influenza A (H1N1) Infection: A Global Pooled Analysis. PLoS Med., 8.